Besides, our results demonstrate a positive correlation between elevated levels of CMTM6 and CD58 expression in tumor cells and the clinical benefits in ICB treatment among a cohort of melanoma patients, suggesting potential clinical significance. This evidence concerns the gene CD58 and neoplasm.